Great questions. Here are the clinical outcomes:
Me (M, 42, started at 265 lbs):
- Current weight: 218 lbs (-47 lbs, 17.7% body weight)
- A1C: 6.4% → 5.3%
- Fasting glucose: 112 → 86 mg/dL
- LDL: 148 → 108 mg/dL
- Triglycerides: 195 → 112 mg/dL
- Blood pressure: 138/88 → 122/76
My partner (F, 39, started at 198 lbs):
- Current weight: 162 lbs (-36 lbs, 18.2% body weight)
- A1C: 5.8% → 5.1%
- Fasting glucose: 98 → 78 mg/dL
- LDL: 132 → 95 mg/dL
Adverse effects: Standard GI side effects during titration for both of us — nausea, reduced appetite (desired), occasional constipation. All resolved by month 2. I had one episode of mild hypoglycemia early on when I skipped a meal. No injection site reactions, no pancreatitis symptoms, no thyroid concerns. We both do comprehensive blood work every 3 months.
These outcomes are consistent with Phase 3 trial data for tirzepatide (SURMOUNT program), which strongly suggests the product is pharmacologically legitimate. Grey market tirz from QSC is doing what name-brand Mounjaro is supposed to do, at 90% lower cost.
Last edited: Feb 9, 2026 at 8:01 AM